{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:31:09Z","timestamp":1791585069121,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P01 CA225618"],"award-info":[{"award-number":["5P01 CA225618"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P30 CA006973"],"award-info":[{"award-number":["5P30 CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jtct.2022.12.009","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T02:24:37Z","timestamp":1671416677000},"page":"267.e1-267.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5911-3873","authenticated-orcid":false,"given":"Cole H.","family":"Sterling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Ling","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Yarkony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-6924","authenticated-orcid":false,"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lode J.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9357-3702","authenticated-orcid":false,"given":"Suman","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H.","family":"Imus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Abbas","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-9653","authenticated-orcid":false,"given":"Alexander","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0545-0708","authenticated-orcid":false,"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian B.","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Varadhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.12.009_bib0001","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.12.009_bib0002","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00277-019-03694-y","article-title":"First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients","volume":"98","author":"Janikova","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0004","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.12.009_bib0005","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0524","article-title":"Recent advances in the treatment of peripheral T-cell lymphoma","volume":"23","author":"Laribi","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jtct.2022.12.009_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-020-00889-z","article-title":"Biomarker-driven management strategies for peripheral T cell lymphoma","volume":"13","author":"Mulvey","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0007","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1016\/S2352-3026(20)30207-6","article-title":"The peripheral T-cell lymphomas: an unusual path to cure","volume":"7","author":"Ma","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0008","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0009","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hon.2705","article-title":"Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials","volume":"38","author":"Ma","year":"2020","journal-title":"Hematol Oncol"},{"issue":"suppl 5)","key":"10.1016\/j.jtct.2022.12.009_bib0010","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0011","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.12.009_bib0012","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.20.01447","article-title":"Is there still a role for allogeneic transplantation in the management of lymphoma?","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0013","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","article-title":"Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation","volume":"77","author":"Jones","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.12.009_bib0014","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0015","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.12.009_bib0016","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/tan.12090","article-title":"Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies","volume":"81","author":"Warren","year":"2013","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jtct.2022.12.009_bib0017","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.12.009_bib0018","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0019","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2018.12.767","article-title":"Development of grade II acute graft-versus-host disease is associated with improved survival after myeloablative HLA-matched bone marrow transplantation using single-agent post-transplant cyclophosphamide","volume":"25","author":"McCurdy","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.12.009_bib0020","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0021","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2022.12.009_bib0022","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.12.009_bib0023","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.12.009_bib0024","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","article-title":"Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.12.009_bib0025","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0026","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0027","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","article-title":"Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"13","author":"Mamez","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0028","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","article-title":"Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.12.009_bib0029","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bmt.2011.16","article-title":"Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas","volume":"47","author":"Delioukina","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.12.009_bib0030","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3109\/10428194.2011.645818","article-title":"Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant","volume":"53","author":"Goldberg","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.12.009_bib0031","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0032","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41409-020-01133-5","article-title":"Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor types on outcome","volume":"56","author":"Castagna","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.12.009_bib0033","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-138542","article-title":"Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis","volume":"136","author":"Mehta-Shah","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.12.009_bib0034","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/bmt.2016.348","article-title":"Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma","volume":"52","author":"Castagna","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.12.009_bib0035","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/leu.2016.125","article-title":"Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European Society for Blood and Marrow Transplantation","volume":"30","author":"Dietrich","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.12.009_bib0036","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0037","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2022.12.009_bib0038","article-title":"Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults","author":"Holtick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtct.2022.12.009_bib0039","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.16182","article-title":"Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma: a LWP-EBMT study","volume":"188","author":"Bazarbachi","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.12.009_bib0040","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3324\/haematol.2012.080895","article-title":"Impact of disease status and stem cell source on the results of reduced- intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"98","author":"Marcais","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.12.009_bib0041","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.18052","article-title":"Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant","volume":"197","author":"Savani","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722018358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722018358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T17:19:40Z","timestamp":1721668780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722018358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2666636722018358"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.12.009","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2007516\/v1","asserted-by":"object"}]},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}